Teclistamab‐cqyv in multiple myeloma
European Journal of Haematology · 2024-03 · 112 (3) · 320-327
DOI: 10.1111/ejh.14121 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 17.10.2023. Verfasst von Enrica Antonia Martino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health, Ministero della Salute.
Abstract (Originalsprache)
Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and mortality. Despite advances in treatment, MM patients eventually experienced a relapse of the disease. Penta‐drug refractory patients continue to be the hard core of relapsed/refractory (RR) settings. Teclistamab‐cqyv is a humanized IgG4 antibody and a bispecific BCMA‐director CD3 T‐cell engager. It recruits endogenous T cells, by targeting CD3 receptors expressed on their surface, resulting in their activation against BCMA, an antigen expressed by plasma cells. US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Teclistamab‐cqyv in monotherapy for the treatment of RRMM patients who have received at least three prior therapies, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti‐CD38 monoclonal antibodies (MoAbs) and have demonstrated disease progression during the last therapy. Its effectiveness was demonstrated in a pivotal clinical trial where the overall response rate (ORR) reached 60%. Other clinical studies are currently ongoing to investigate the association of the bispecific antibody with novel drugs with encouraging preliminary results, especially in the setting of heavily pretreated patients. In this review, the authors will provide a comprehensive overview of the drug, including its mechanism of action, major clinical trials, and future perspectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
- Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy.
- Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Antonella Bruzzese, Fortunato Morabito
Förderung
- Italian Ministry of Health
- Ministero della Salute
Zitieren
APA
Martino, E. A., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Neri, A., Morabito, F., Vigna, E., & Gentile, M. (2024). Teclistamab‐cqyv in multiple myeloma. European Journal of Haematology, 112(3), 320-327. https://doi.org/10.1111/ejh.14121
Vancouver
Martino EA, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, et al. Teclistamab‐cqyv in multiple myeloma. European Journal of Haematology. 2024;112(3):320-327. doi:10.1111/ejh.14121
BibTeX
@article{Martino2024,
author = {Martino, Enrica Antonia and Bruzzese, Antonella and Labanca, Caterina and Mendicino, Francesco and Lucia, Eugenio and Olivito, Virginia and Neri, Antonino and Morabito, Fortunato and Vigna, Ernesto and Gentile, Massimo},
title = {Teclistamab‐cqyv in multiple myeloma},
journal = {European Journal of Haematology},
year = {2024},
volume = {112},
number = {3},
pages = {320--327},
doi = {10.1111/ejh.14121}
}
EUVIMED